Pemetrexed, Platinum Chemo Demonstrates Better Disease Control in NSCLC

Share this content:
Platinum combination with pemetrexed resulted in better disease control and improved survival in patients with non-small cell lung cancer.
Platinum combination with pemetrexed resulted in better disease control and improved survival in patients with non-small cell lung cancer.

A retrospective analysis showed that a platinum combination with pemetrexed resulted in better disease control and improved survival in patients with non-small cell lung cancer who progressed following first-line treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) compared with those treated with pemetrexed alone.1

Platinum-based combination therapy is recommended in patients who have failed first-line treatment with EGFR TKIs, however the question of which agent is best remains.

Investigators sought to determine the safety and efficacy of  pemetrexed compared with a combination of pemetrexed/platinum-based chemotherapy.

Investigators analyzed 63 patients who received pemetrexed-based therapy after failure of an EGFR-TKI. Patients were treated with either with pemetrexed/platinum combination therapy (n=34) or pemetrexed 500 mg/m2 alone (n=29).

The pemetrexed-platinum group displayed higher overall response rate compared to the pemetrexed alone group (44.4% vs 25.9%, respectively; P=0.154) Disease control rates were also superior in the combination arm (75.0% vs 43.5%, respectively; P=0.017).

After 9.6 months, median progression-free survival was 5.2 months (95% CI: 3.8-6.7 months) in the pemetrexed-platinum group (P=0.096) and 2.7 months (95% CI: 1.5-3.9 months) in the pemetrexed group.

Median overall survival was 15.1 months (95% CI: 12.8-17.4 months) and 10.3 months (95% CI: 8.9-11.6 months), respectively (P=0.354).

RELATED: Targeted Therapies Associated With Increased Alopecia Risk

Common adverse events included fatigue, nausea, and neutropenia. Neutropenia only occurred within the pemetrexed-platinum group (18%; P=0.049), and none of the cases were febrile.

The authors concluded that a pemetrexed plus platinum regimen may be suitable as second-line therapy, but prospective, phase 2 studies are required to further assess its appropriateness.

Reference

  1. Lee SJ, Sun JM, Lee SH, et al. Pemetrexed plus platinum versus pemetrexed alone in non-small cell lung cancer patients who have progressed after first-line EGFR TKIs.[published online ahead of print September 3, 2015]. Lung Cancer. doi: 10.1016/j.lungcan.2015.08.020.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs